Original Research Article

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate [a, b, c, *, ‡]

Douglas J. Taylor a, *, Vera Halpern a, Vivian Brache b, Luis Bahamondes c, Jeffrey T. Jensen d, Laneta J. Dorflinger d

a FHI 360, Durham, NC, United States
b Profamilia, Biomedical Research Department, Santo Domingo, Dominican Republic
c Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences, Campinas, Brazil
d Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, United States

A R T I C L E   I N F O

Article history:
Received 30 October 2021
Revised 5 February 2022
Accepted 11 February 2022

Keywords:
DMPA
Depo-Provera
Depo-subQ Provera
Pharmacokinetics
Pharmacodynamics

A B S T R A C T

Objectives: To characterize the relationship between serum medroxyprogesterone acetate (MPA) concentrations and ovulation suppression, and to estimate the risk of ovulation for investigational subcutaneous regimens of Depo-Provera Cl (Depo-Provera) and Depo-subQ Provera 104 (Depo-subQ).

Study Design: We performed a secondary analysis of 2 studies that assessed the pharmacokinetics and pharmacodynamics of MPA when Depo-Provera is administered subcutaneously rather than by the labeled intramuscular route. Each woman received a single 45 mg to 300 mg subcutaneous injection of Depo-Provera, a single 104 mg subcutaneous injection of Depo-subQ, or 2 injections of Depo-subQ at 3-month intervals. We used an elevation of serum progesterone ≥4.7 ng/mL as a surrogate for ovulation and non-parametric statistical methods to assess pharmacokinetic and pharmacodynamic relationships.

Results: This analysis included 101 women with body mass index (BMI) 18 to 34 kg/m². Return of ovulation occurred at a median MPA concentration of 0.07 ng/mL (95% CI 0.06–0.08) and the 90th percentile was 0.10 ng/mL (95% CI: 0.09–0.14). Neither age, race, nor BMI significantly influenced this relationship. The estimated probabilities of ovulation within 4 months of a 104 mg subcutaneous injection and within 7 months of a 150 mg subcutaneous injection (6 plus a 1-month grace) were each below 2.2%.

Conclusions: The typical MPA concentration associated with loss of ovulation suppression is substantially less than the commonly cited threshold of 0.2 ng/mL. Based on our results, MPA levels would rarely be low enough to permit ovulation if the Depo-subQ reinjection interval were extended to four months or if 150 mg Depo-Provera were injected subcutaneously every 6 months.

Implications: Extending the three-month Depo-subQ reinjection interval by one month would result in a 25% reduction in yearly MPA exposure, with little risk of pregnancy. Off-label subcutaneous administration of 150 mg Depo-Provera every 6 months would be a highly effective repurposing of an excellent product, with a similar reduction in cumulative exposure.

* Data sharing: After de-identification, individual participant data from both studies analyzed here will be submitted to the Development Data Library (DDL), USAID’s publicly available repository for Agency-funded data-on-demand.

** Declaration of Competing Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

a Role of the funding source: This work is made possible by the generous support of the American people through the U.S. Agency for International Development (US-AID), provided to FHI 360 through Cooperative Agreement AID-OAA-A-15-00045, and through grant number OPP 1055878 from The Bill & Melinda Gates Foundation (BMGF), which funded one of the trials included in the analysis. The funders were not involved in the analysis, interpretation, or writing of this report. The contents are the responsibility of FHI 360, and do not necessarily reflect the views of USAID, the United States Government, or BMGF. Nor does any mention of trade names, commercial products, or organizations imply endorsement by FHI 360, USAID, the United States Government, or BMGF.

© 2022 The Author(s). Published by Elsevier Inc.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

1. Introduction

The intramuscular injectable Depo-Provera Cl (150 mg depot medroxyprogesterone acetate [MPA] in 1 mL suspension) (Depo-Provera) is a highly effective contraceptive method, with a pregnancy rate of 0.3 per 100 person-years when injected every 3

https://doi.org/10.1016/j.conx.2022.100073
2590-1516 © 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

[Image]
months [1]. A lower dose subcutaneous formulation supplied in a
pre-filled glass syringe, Depo-subQ Provera 104 (104 mg MPA in
0.65 mL suspension) (Depo-subQ), is also injected every 3 months.
Despite a 31% lower dose, Depo-subQ achieves comparable effi-
cacy to Depo-Provera due to slower drug absorption for the sub-
cutaneous route of administration [1]. Depo-subQ is also associ-
ated with a similar side effects profile as Depo-Provera, including
bleeding disturbances, weight gain, reduced mineral bone density,
and delayed return to fertility [2–4].

Prescribing information for Depo-subQ emphasizes the need to
re-inject every 3 months, noting the risk of ovulation as early as
14 weeks after initiating treatment [4]. Based on the pharmacoki-
etics (PK) and pharmacodynamics (PD) studies that supported
approval of Depo-subQ in the USA and Sayana Press (the same drug
pre-filled in a Unijet delivery system) in Europe, a serum progester-
tone concentration ≥4.7 ng/mL (the primary surrogate for ovula-
tion used in the studies) may occur still earlier [5–8]. These events
were typically attributed to an unexpected pharmacokinetics pro-
file (as might occur with an incomplete injection) or inconsistent
with actual ovulation based on supportive gonadotropin hormone
data. Regardless, the risk of an early ovulation is clearly low, and
accumulation of MPA levels over 1 to 2 years of use implies that
the residual chance of ovulation decreases (and the delay in return
to fertility increases) with continued use of the method [3].

The side effect profile coupled with a lack of appreciable ovu-
lation risk for Depo-subQ has led various researchers to consider regimens that could further reduce MPA exposure [9]. Here we
present a secondary analysis of 2 contemporary pharmacokinetics
and pharmacodynamics studies designed to inform such stratetegies [10,11]. Our initial aim was to characterize the distribution of
serum MPA concentrations when ovulation returns. We leveraged
this relationship to gain further insight into the contraceptive po-
tential of 2 specific approaches to reducing MPA exposure by ap-
proximately 25% compared to the current subcutaneous regimen:
extending the Depo-subQ injection interval from 3 to 4 months
and repurposing the existing 3-month Depo-Provera intramuscular
product as a 6-month subcutaneous method.

2. Materials and methods

We performed a secondary analysis of 2 contemporary pharma-
cokinetics and pharmacodynamics studies of subcutaneously ad-
ministered MPA conducted between September 2015 and May 2018
[10,11]. Briefly, FHI 360 Study number 702179 (Clinical Trial Regis-
tration Number NCT02456584) randomized 36 women from sites
in the Dominican Republic and the USA to receive a single 150 mg
(1 mL) or 300 mg (2 mL) subcutaneous injection of Depo-Provera,
or two 104 mg (0.65 mL) subcutaneous injections of Depo-subQ
at 3-month intervals, in a 2:1:1 ratio. An additional 6 women were
purposefully assigned to the 150 mg group, and one withdrew con-
sent, leaving 41 treated subjects. Women were followed for a min-
imum of 7.5 months and then until ovulation was detected, but
for a maximum of 18 months. We measured serum progesterone
concentrations weekly starting 12 weeks after each injection. Par-
ticipants who did not have an elevated progesterone concentration
≥4.7 ng/mL within 12 months of treatment initiation returned for
weekly progesterone assessments in month 15 and (if still anovu-
latory) again in month 18 (the visit schedule within 12 weeks of
injection and supportive pharmacodynamic measures are detailed
elsewhere [10], FHI 360 Study number 834119 (NCT02732418) ran-
domized 60 participants in the Dominican Republic, Chile, and
Brazil to receive a single 45 mg (0.3 mL), 75 mg (0.5 mL), or
105 mg (0.7 mL) subcutaneous injection of Depo-Provera, or a sin-
gle 104 mg subcutaneous injection of Depo-subQ, in a 1:1:1:1 ra-
tio [11]. We measured serum progesterone levels at least weekly
until ovulation was confirmed or month 7.5, whichever was ear-
lier. However, all Study 834119 participants contributed a full 7.5
months of MPA testing, regardless of ovulation status (details of
the testing algorithms, including other pharmacodynamic mea-
sures, are described elsewhere [11]).

In both studies, Depo-Provera was drawn from 1 mL vials and
delivered subcutaneously through the same gauge and length need-
le as the Depo-subQ pre-filled syringe (26 G × 3/8”); treatment
was initiated within the first five days of menses; and all injec-
tions were given subcutaneously in the abdomen. Serum MPA
concentrations were determined using a high-performance liq-
uid chromatography-mass spectrometry assay at a central labora-
tory (PPD Development; Richmond, VA) with accuracy −3.0% to
3.7% and interassay CV of 4.5% to 10.5%. Progesterone concentra-
tions were determined at local laboratories using commercial elec-
trochemiluminescence immunoassays (Roche Elecsys 2010, Roche
Cobas e411, and Siemens Advia Centaur) with sensitivity ≤0.05
ng/mL and interassay CV less than 10%. The FHI 360 Protection of
Human Subjects Committee and ethics boards applicable to each
research site approved the studies.

One noteworthy difference between the two protocols was that
Study 702179 used a single elevated progesterone ≥4.7 ng/mL as
a surrogate for ovulation while Study 834119 incorporated follicu-
lar rupture in the ovulation algorithm. Here we define presump-
tive ovulation as a single elevated progesterone ≥4.7 ng/mL to
harmonize measurements between studies and with historical data.
A second important difference was that Study 702179 exited partici-
ants when ovulation was detected. Accounting for this type of In-
formative censoring when jointly modeling longitudinal MPA and
time to ovulation data with nonlinear mixed-effects (population
PK/PD) models requires making additional assumptions for already
complex analysis methods [12]. We instead used a nonparametric,
2-stage estimation procedure to minimize assumptions regarding
drug absorption rates, censoring mechanisms, and distributions of
random variables.

In stage 1, we estimated each participant’s underlying pharma-
cokinetics profile based on their rich sample of MPA measurements
(a minimum of 23 specimens over the first 7.5 months of follow-
up) using locally re-weighted nonparametric regression (LOESS),
which accounts for measurement error and potential outliers in
observed values over time [13]. We used these profiles to predict
each participant’s MPA concentration on the last day when elev-
ad progesterone could be ruled out and the first day that an ele-
vated progesterone was detected. This interval, which ranged
from 2 to 9 days in length among participants who ovulated before
month 12, was fixed at 56 days for participants in Study 702179
who did not have ovulation detected until month 15 or 18, since
up to two 28-day menstrual cycles could have been missed in the
testing gaps after month 12. Participants who never had ovula-
tion detected had their MPA levels censored at the maximum of
the concentration predicted for the day they ended testing and the
lower limit of quantification (0.02 ng/mL). In stage 2, we estimated
the cumulative distribution of MPA concentrations when ovulation
returned by applying Turnbull’s nonparametric maximum likeli-
hood algorithm to the censored stage 1 data [14]. Distributions of
MPA concentrations at other relevant timepoints (e.g., 7 months
after a 150 mg dose) were similarly obtained. We used parametric
alternatives to Turnbull’s algorithm, selected based on Bayesian In-
formation Criteria, to compute bootstrap confidence intervals (CI),
estimate covariate effects, and perform sensitivity analyses.

If we can assume that the MPA concentration required to sup-
press an individual’s ovulation (denoted by the random variable
$Y_{ov}$) does not vary with time or extent of exposure, then the pro-
bability they ovulate within T months of injection is simply the prob-
ability that their MPA level falls below $Y_{ov}$ on or before month T.
The probability of this occurring can be approximated by the fol-
lowing equation:

\[ p_T(Y_T < Y_{0.05}) = \int_0^{Y_{0.05}} f_Y(y) \, dy. \]  

(Equation 1)

where \( f_Y(\cdot) \) is the cumulative distribution of the MPA concentration at month \( T \) (denoted \( X_T \)) and \( f_Y(\cdot) \) is the cumulative distribution of \( Y_{0.05} \). Since MPA concentrations may not uniformly decrease with time since injection, it would be more accurate to replace the distribution of MPA at month \( T \) in Eq. (1) with the distribution of the minimum concentration on or before month \( T \) (\( X_{\text{min}} \)). However, this distinction was not of practical importance for the formulations, doses, and time periods relevant to our analyses. Using \( X_T \) in place of \( X_{\text{min}} \) also facilitates finding a solution when – contrary to our setting – MPA data are sparse and the distribution of \( X_{\text{min}} \) cannot be reliably obtained. We solved Eq. (1) using both nonparametric and parametric methods when estimating the probability of ovulation within four months of a 104 mg injection and within seven months (6 plus a 1-month grace) of a 150 mg injection. Additional details are in the supplemental Appendix. All analyses were performed using SAS/STAT or SAS/IML Version 9.4.

3. Results

3.1. Demographics and participant disposition

Detailed characteristics of the 101 participants contributing to our analyses are in the previous manuscripts \([10,11]\). Briefly, the median age was 34 years (range 22–40); 35.6% self-identified as white and 64.4% identified as black or biracial; and the median body mass index (BMI; kg/m²) was 26.6 (range 18.1–33.9; Table 1). Fifty-nine participants (58.4%) had ovulation detected during follow-up. We excluded 6 participants (5.9%) from pharmacokinetics analyses due to elevated MPA in their baseline specimens and one (1.0%) from pharmacodynamics analyses due to the use of a medication which may have impacted ovulatory function.

3.2. Pharmacokinetics and pharmacodynamics data

The 150 mg and 300 mg dose groups exhibited pronounced bi-phasic drug absorption on average, with a secondary peak after day 30 (Fig. 1). Individual pharmacokinetic profiles were decidedly heterogeneous, variously exhibiting burst effects, near zero-order absorption for extended time periods, and other complex absorption patterns (Supplemental Fig. S1). The geometric mean (GM) maximum concentration (\( C_{\text{max}} \)) ranged from 0.35 ng/mL (45 mg) to 1.74 ng/mL (300 mg), with the increase proportional to dose in the 45mg to 150mg range (supplemental Table S1). Geometric mean MPA levels were generally higher for 104 mg Depo-subQ than for subcutaneous administration of 105 mg Depo-Provera, due in part to one participant in the 105 mg group with unusually low levels throughout follow-up (PN 2321, Supplemental Fig. S1). Geometric mean concentrations were proportional to dose between month 1 and month 4, but decreased more rapidly thereafter in the 45 mg, 75 mg, and 105 mg groups (the same is apparent when considering the GM of the minimum MPA concentration on or before month \( T \); supplemental Table S2). Average MPA levels appeared to plateau near 0.1 ng/mL after month 9 in the 150 mg group, consistent with informative censoring due to discontinuing participants when ovulation occurred in Study 702179.

None of the 15 participants who received a single subcutaneous injection of 104 mg Depo-subQ ovulated during 7.5 months of follow-up, and only 1 of 9 who received a second dose at month three ovulated within 9 months of their second injection. The earliest ovulation among participants who received a 45 mg, 75 mg, 105 mg, 150 mg, or 300 mg subcutaneous injection of Depo-Provera occurred at month 0.2, 0.5, 5.5, 7.5, and 11, respectively (Fig. 2).

3.3. Serum MPA concentrations and ovulation suppression

The LOESS-predicted MPA concentrations at timepoints relevant to analyses exhibited excellent fits to the data (Supplemental Fig. S2). The nonparametric estimate of the median MPA concentration when ovulation returned was 0.07 ng/mL (95% CI: 0.06–0.08), the 90th percentile was 0.10 ng/mL (95% CI: 0.09–0.14), and no participants ovulated at concentrations exceeding 0.2 ng/mL (Fig. 3). Assuming \( Y_{0.05} \) was sampled from a Weibull distribution led to similar results (median: 0.06 ng/mL; 90th percentile: 0.11 ng/mL). Neither study, age, race, BMI, nor administered dose were significantly associated with the MPA concentration when ovulation returned, but a faster rate of MPA decline in the 2 to 4 weeks prior to ovulation was associated with lower MPA levels when progesterone became elevated (\( p = 0.02; \) Table 2).

---

Table 1

Demographic characteristics and participant disposition in two trials conducted between 2015 and 2018 that assessed the pharmacokinetics and pharmacodynamics of MPA when Depo-Provera is administered subcutaneously rather than by the labeled intramuscular route [10,11].

| Characteristic                  | Study 702179 (n = 41) | Study 834119 (n = 60) | Total (n = 101) |
|--------------------------------|-----------------------|-----------------------|-----------------|
| Age (years)                    |                        |                       |                 |
| Median (Range)                 | 34 (25–39)            | 33 (22–40)            | 34 (22–40)      |
| > 35                           | 16 (39.0%)            | 24 (40.0%)            | 40 (39.6%)      |
| Race                           |                        |                       |                 |
| White                          | 7 (3.3%)              | 33 (55.0%)            | 36 (35.6%)      |
| Biraical or black              | 38 (92.7%)            | 27 (45.0%)            | 65 (64.4%)      |
| BMI (kg/m²)                    |                       |                       |                 |
| Median (Range)                 | 26.6 (18.1–32.8)      | 26.7 (19.0–33.9)      | 26.6 (18.1–33.9) |
| < 25                           | 13 (31.7%)            | 21 (35.0%)            | 34 (33.7%)      |
| 25 to 30                       | 18 (43.9%)            | 25 (41.7%)            | 43 (42.6%)      |
| > 30                           | 10 (24.4%)            | 14 (23.3%)            | 24 (23.8%)      |
| Study disposition              |                       |                       |                 |
| Completed follow-up            | 41 (100%)             | 54 (90.0%)            | 95 (94.1%)      |
| Ovulated                       | 35 (85.4%)            | 24 (40.0%)            | 59 (58.1%)      |

1 Study 702179 [10] was conducted in the Dominican Republic and the USA. Study 834119 [11] was conducted in Brazil, Chile, and the Dominican Republic. Data presented are n (%) unless otherwise noted.

2 Greater than 90% of participants identifying as biracial were of African and European descent.

3 Includes 16 ovulations detected after the primary 12-month follow-up period.
Fig. 1. Geometric mean MPA concentrations following subcutaneous administration of 45–300 mg Depo-Provera or 104 mg Depo-subQ in two trials conducted between 2015 and 2018 [10,11]. Solid lines and 95% confidence bands are based on locally re-weighted nonparametric regression. The first three months of data were pooled for participants receiving one (x1) or two (x2) injections of Depo-subQ. Abbreviation: MPA, medroxyprogesterone acetate.

Fig. 2. Cumulative probability of ovulation (progesterone ≥4.7 ng/mL) following subcutaneous administration of 45–300 mg Depo-Provera or 104 mg Depo-subQ in two trials conducted between 2015 and 2018 [10,11]. Shaded regions are 95% confidence bands. Numbers at-risk are below the x-axis. There were no events among subjects who received a single (x1) dose of Depo-subQ.

3.4. Probability of ovulation within 4 or 7 months of a 104 mg or 150 mg injection

We included all 95 evaluable participants in all dose groups (normalized to 104 mg) when estimating the cumulative distribution of MPA levels 4 months after a 104 mg subcutaneous injection ($X_{m4}$). The nonparametric estimate of the median concentration at month 4 was 0.31 ng/mL (95% CI: 0.28–0.32) and 90% of participants exceeded 0.17 ng/mL (95% CI: 0.14–0.19; Fig. 4). A sensitivity analysis restricted to just the 39 participants in the 104 mg and 105 mg groups led to similar results (median: 0.30 ng/mL; 10th percentile: 0.18 ng/mL).

We only included the 29 evaluable participants in the 150 mg and 300 mg groups (normalized to 150 mg) when estimating the cumulative distribution of MPA levels 7 months after a 150 mg subcutaneous injection ($X_{m7}$), owing to the lack of dose-proportionality in the lower dose groups. The estimated median concentration was 0.25 ng/mL (95% CI: 0.20–0.30) and 90% of participants exceeded 0.17 ng/mL (95% CI: 0.00–0.20; Fig. 4). Restricting the analysis to just the 21 evaluable participants in the 150 mg
Fig. 3. Cumulative distribution of the MPA concentration when ovulation returns (progesterone ≥ 4.7 ng/mL) following subcutaneous administration of 45–300 mg Depo-Provera or 104 mg Depo-subQ in two trials conducted between 2015 and 2018 [10,11]. Dashed lines and 95% confidence bands are based on non-parametric maximum likelihood estimation. Solid curve is Weibull model fit, which was used to estimate covariate effects in Table 2. Abbreviation: MPA, medroxyprogesterone acetate.

Fig. 4. Cumulative distribution of MPA concentrations 4 months after a 104 mg subcutaneous injection (n = 95; left) and seven months after a 150 mg subcutaneous injection (n = 29; right), based on data from two trials conducted between 2015 and 2018 [10,11]. Dashed lines and 95% confidence bands are based on non-parametric maximum likelihood estimation. Solid curves are parametric model fits. Abbreviation: MPA, medroxyprogesterone acetate.

group led to similar results (median: 0.25 ng/mL; 10th percentile: 0.18 ng/mL). Neither age nor race was significantly associated with the distribution of MPA at month 4 or 7. Body mass index greater than 30.0 was associated with lower MPA concentrations at month 4, but only in a sensitivity analysis restricted to the 39 participants who received a 104 mg or 105 mg dose (of whom only 6 were in the high BMI category; Supplemental Table S3).

We estimated the probability of ovulation within 4 months of a 104 mg subcutaneous injection to be 1.5% when randomly sampling 50,000 replicates from the empirical distributions of $Y_{m4}$ (Fig. 3) and $X_{m4}$ (Fig. 4) to solve Eq. (1). Assuming these were each distributed as Weibull random variables led to a similar result (1.3%; 95% bootstrap CI: 0.5–2.3). The estimated probability of ovulation within 7 months of a 150 mg subcutaneous injection was 2.1% when randomly sampling from the empirical distributions of $Y_m$ and $X_{m7}$, and 0.4% (95% CI: 0.1–1.4) when assuming these variables were distributed Weibull and log-normal, respectively (the discrepancy between the latter non-parametric and parametric solutions may be attributed to a conservative assumption made when sampling from the empirical distribution of $X_{m7}$; see supplemental Appendix).
Table 2
Median MPA concentration (ng/mL) when ovulation returns following subcutaneous administration of 45–300 mg Depo-Provera or 104 mg Depo-subQ in two trials conducted between 2015 and 2018 [10,11]. All results are based on a Weibull distribution assumption.

| N  | Median (95% CI)  | pvalue |
|----|-----------------|--------|
| Overall | 98 | 0.064 (0.055, 0.074) | NA |
| Study number | 702179 | 0.065 (0.055, 0.077) | |
| 834119 | 57 | 0.062 (0.051, 0.076) | |
| BMI (kg/m²) | <25 | 0.059 (0.048, 0.072) | 0.36 |
| 25–30 | 42 | 0.070 (0.058, 0.084) | |
| >30 | 23 | 0.062 (0.048, 0.079) | |
| Age (years) | <35 | 0.064 (0.054, 0.075) | 0.87 |
| >35 | 39 | 0.065 (0.053, 0.080) | |
| Race | Black/biracial | 0.09 |
| White | 64 | 0.068 (0.058, 0.079) | |
| Half-life (days)* | <.45 | 0.055 (0.045, 0.067) | 0.02 |
| 45–70 | 31 | 0.064 (0.053, 0.078) | |
| >90 | 34 | 0.079 (0.064, 0.097) | |
| Dose of MPA | 98 | NA | 0.37 |

MPA, medroxyprogesterone acetate.
* Corresponding to rate of MPA decrease in the 2–4 weeks prior to last non-elevated progesterone measurement.

4. Discussion

Prescribing information for Depo-subQ emphasizes the need to adhere to a 3-month dosing schedule [4]. Although ovulations can still occur, such events are rare, and no pregnancies were detected in phase 3 trials of the regimen. In our pharmacokinetics and pharmacodynamics studies, 0 of 30 participants who received a single 104 mg or 105 mg subcutaneous injection of MPA experienced an elevated serum progesterone concentration ≥4.7 ng/mL before month 5.5, and 0 of 21 who received a 150 mg subcutaneous injection ovulated by this criterion before month 7.5 (qualitatively similar findings were obtained using a progesterone threshold of 3.0 ng/mL: results not shown). Our modeling results that leveraged data from all (45–300 mg) dose groups were consistent with the empirical evidence: less than a 2.2% chance of ovulation within four months of a 104 mg subcutaneous injection of MPA or within 7 months of a 150 mg subcutaneous injection of MPA. We also estimated that 90% of women do not ovulate until their serum MPA concentration falls below 0.10 ng/mL, and 50% do not ovulate until their MPA level falls below 0.07 ng/mL. These results emphasize that the commonly cited MPA threshold of 0.2 ng/mL is too high for the majority of women, and that the 0.1 ng/mL level noted by others is a more reasonable guidance [6,15].

Our study results are consistent with some but not all historical trials of Depo-subQ. We observed geometric mean Cmax values of 0.80 to 0.82 ng/mL in the 104 mg and 105 mg dose groups that were lower than the mean (median) of 1.56 (1.49) ng/mL reported in the Depo-subQ label study [5,6]. We also observed a more extended drug release profile and a longer delay in return to ovulation than in the label study (Supplemental Fig. S3). Although population differences may partially explain this, site of injection could also play a role. The injection site is not noted in references for the label study, while we exclusively gave subcutaneous injections in the abdomen. The latter was associated with a lower Cmax than injections in the thigh in another trial [7]. On the other hand, our results are consistent with a comparative study of 64 women who received subcutaneous injections of Depo-subQ (104 mg MPA in glass syringe) or Sayana Press (104 mg MPA in the Uniject device) [8]. That trial reported a GM Cmax of 0.79 ng/mL for Depo-subQ, which is essentially identical to our result. And although there was one ovulation before month 3 in each device group (excluding women with dose administration errors), none occurred between 3 and 5 months of injection. Some differences between contemporary and historical studies could arise due to overfill of the Depo-subQ glass syringe, which may not have been used in trials that predate approval of the product [11]. We conducted sensitivity analyses that accounted for up to 10% overfill, but the results did not meaningfully change. However, the predicted MPA concentration 6 months after a 150 mg dose was equivalent to the level 3 months after a 104 mg dose when adjusting for overfill (GM ratio: 0.94; 90% CI: 0.80–1.11), lending further support to a 6-month 150 mg regimen.

There are several limitations to our analysis, most importantly the absence of participants with class II+ obesity (BMI ≥35). We did not observe consistent trends between risk of ovulation and BMI in the range of 18 to 34, which agrees with earlier reports [6]. However, this does not mean our results necessarily apply to women with more extreme BMI. To the best of our knowledge the relationship between pharmacokinetics and pharmacodynamics of MPA in class II+ obesity has only been formally assessed in one study, making this a valuable area of future research [16]. A second limitation is the racial diversity of our study participants, who primarily identified as Caucasian or biracial of African and European descent. Although the pharmacokinetics and pharmacodynamics of Depo-subQ is reported to be similar for Caucasian, African American, and Asian women, we cannot rule out important differences among other racial groups [4]. Pharmacogenetic research to identify factors that impact the pharmacokinetics or pharmacodynamics of MPA and their potential associations with geographic region, race or ethnicity is another important area of future research. A third limitation is that the MPA level associated with elevation of progesterone ≥4.7 ng/mL is expected to be somewhat lower than the level required to suppress ovulation due to the delay between these events. Our observation that women with faster rates of MPA decline tended to have lower drug levels when progesterone became elevated is consistent with this delay. In a sensitivity analysis, however, the median MPA level ten days prior to when progesterone became elevated was still only 0.08 ng/mL (90th percentile: 0.12 ng/mL). Finally, we implicitly extrapolated beyond the range of the data when modeling the probability of rare outcomes (e.g., ovulation within 4 months of a 104 mg or 105–mg injection, when no such events occurred). Fully parametric population PK/PD models could increase precision in this setting but may not perform well when assumptions underlying them are misspecified [17]. We tried to minimize model assumptions by using nonparametric methods but cannot rule out biases.

It is distinctly possible that any real-world Depo-subQ contraceptive failures are disproportionately attributable to issues largely unrelated to dose, such as mistimed treatment initiation or inadvertent injection near a vascular site. The use of an unnecessarily high exposure to limit the residual chance of treatment failure would be a disservice to the vast majority of women if a lower exposure can reduce side effects, costs, or otherwise make the product more acceptable. Our secondary analysis reinforces conclusions in one of the constituent study manuscripts that there would be little risk of pregnancy if the Depo-subQ rejections interval were extended from 3 to 4 months [11]. This has since been confirmed in an efficacy trial that observed a pregnancy rate of 0.00 per 100 women-years (95% CI: 0.00–0.59) among 750 women injecting Sayana Press every four months [18]. A 150mg subcutaneous injection of Depo-Provera every 6 months (with up to a 1-month grace period) also appears highly effective, could be more acceptable due to less frequent injections, and would reduce long-term MPA exposure by 28% compared to the existing Depo-subQ regimen.
Acknowledgments

We are grateful to the study participants and research staff at PROFAMILIA (Dominican Republic), Universidade Estadual de Campinas (Brazil), Instituto Chileno de Medicina Reproductiva (Chile), and Oregon Health and Science University (USA) for contributing the study data used in our analyses.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.conx.2022.100073.

References

[1] Jain J, Jakinuiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004;70:269–75.
[2] Dragoman MV, Gaffield ME. The safety of subcutaneously administered depot medroxyprogesterone acetate (104 mg/0.65 mL): a systematic review. Contraception 2016;94:202–15.
[3] Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception 2009;80:7–17.
[4] DEPO-SUBQ PROVERA 104® [prescribing information] Pharmacia and upjohn, New York, NY: Division of Pfizer Inc. 2020. Revised December.
[5] U.S. Food and Drug Administration. Depo-subQ Provera 104 (Medroxyprogesterone acetate) injectable suspension new drug application no.: 021583. Center for Drug Evaluation and Research Clinical Pharmacology and Biometrics Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021583s000_ClinPharmR.pdf (accessed April 25, 2021).
[6] Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode FR, Mishell DR. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera®. Contraception 2004;70:11–18.
[7] Toh YC, Jain J, Rahimy MH, Bode FR, Ross D. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Clin Ther 2004;26:1845–54.
[8] Medicines and Healthcare Products Regulatory Agency (MHRA). Public assessment report, mutual recognition procedure, Sayana 104 mg/0.65 mL suspension for injection. Revised August 2015. (https://products.mhra.gov.uk/on Accessed April 25, 2021).
[9] Shelton JD, Halpern V. Subcutaneous DMPA: a better lower dose approach. Contraception 2014;89:341–3.
[10] Halpern V, Brache V, Taylor D, Lendvay A, Cochón L, Jensen J, et al. Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera. Fertil Steril 2021;115:1035–43.
[11] Halpern V, Fuchs R, Brache V, Bahamondes L, Miranda M, Lendvay A, et al. Suppression of ovulation and pharmacokinetics following subcutaneous administration of various doses of Depo-Provera®: a randomized trial. Contraception X 2021;3:100070.
[12] Tsilias AA, Davidian M. Joint modeling of longitudinal and time-to-event data: an overview. Stat Sinica 2004;14:809–34.
[13] Cleveland WS, Grosse W. Computational methods for local regression. Stat Comput 1991;1:47–62.
[14] Turnbull BW. The empirical distribution function with arbitrarily grouped, censored, and truncated data. J R Statist Soc B 1976;38:290–5.
[15] Ortiz A, Hiroi M, Stanczyk F, Goebelsmann U, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intra-muscular injection of Depo-MPA. J Clin Endocrinol Metab 1977;44:32–48.
[16] Segall-Gutierrez F, Taylor D, Liu X, Stanczyk F, Azen S, Mishell DR Jr. Folicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception 2010;81:487–95.
[17] Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods. J Pharmacokinet Pharmacodyn 2003;30:405–16.
[18] Deese J, Brache V, Bahamondes L, Salinas A, Jorge A, Veiga Jr N, et al. Contraceptive effectiveness, pharmacokinetics, and safety of Sayana® Press when injected every four months: a multicenter phase 3 trial. eClinicalMedicine 2022;4;101273.